GLPwatch
A Comparison of Exenatide and Insulin Glargine
NCT02325960 · Completed
Last updated 2026-05-28This clinical trial compares the effects of exenatide and insulin glargine on blood sugar fluctuations in adults with type 2 diabetes.
Status Completed The study has finished.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 44 people
Who can join Ages 18–70 · all sexes
Timeline Started 2015-01 · est. completion 2016-10
Where 1 site · China
What this study is testing ClinicalTrials.gov NCT02325960 ↗
Description as written by the study sponsor.
This is a 16-week, Single-center, Randomized, Open Label, Parallel Controlled Group Comparison of the Comprehensive Glycemic Control of Exenatide and Insulin Glargine on Type 2 Diabetes Patients Inadequately Controlled With Metformin Monotherapy.
Treatments tested
- exenatide also known as Byetta.Lilly Drug
5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
- Insulin glargine also known as Lantus,Sanofi Aventis Drug
≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.
| Main thing measured | Mean amplitude of glycemic excursions (MAGE) change from baseline by continuous glucose monitoring system (CGMS) |
|---|---|
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Conditions studied | Type 2 Diabetes |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02325960 ↗